Abbosh C, Birkbak NJ, Wilson GA et al (2017) Phylogenetic ctDNA analysis depicts early stage lung cancer evolution. Nature 545:446–451. https://doi.org/10.1038/nature22364

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abbosh C, Birkbak NJ, Swanton C (2018) Early stage NSCLC — challenges to implementing ctDNA-based screening and MRD detection. Nat Rev Clin Oncol 15:577–586. https://doi.org/10.1038/s41571-018-0058-3

Article  CAS  PubMed  Google Scholar 

Aggarwal C, Thompson JC, Chien AL et al (2020) Baseline plasma Tumor Mutation Burden predicts response to Pembrolizumab-based Therapy in patients with Metastatic non–small cell Lung Cancer. Clin Cancer Res 26:2354–2361. https://doi.org/10.1158/1078-0432.CCR-19-3663

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anagnostou V, Forde PM, White JR et al (2019) Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer. Cancer Res 79:1214–1225. https://doi.org/10.1158/0008-5472.CAN-18-1127

Article  CAS  PubMed  Google Scholar 

Anagnostou V, Niknafs N, Marrone K et al (2020) Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. Nat Cancer 1:99–111. https://doi.org/10.1038/s43018-019-0008-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anagnostou V, Landon BV, Medina JE et al (2022) Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy. Sci Transl Med 14:eabo3958. https://doi.org/10.1126/scitranslmed.abo3958

Article  CAS  PubMed  PubMed Central  Google Scholar 

Assaf ZJF, Zou W, Fine AD et al (2023) A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer. Nat Med 29:859–868. https://doi.org/10.1038/s41591-023-02226-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

AstraZeneca (2019) Update on the Phase III NEPTUNE trial of Imfinzi plus Tremelimumab in Stage IV nonsmall cell lung cancer

Avanzini S, Kurtz DM, Chabon JJ et al (2020) A mathematical model of ctDNA shedd-ing predicts tumor detection size. Sci Adv 6:eabc4308. https://doi.org/10.1126/sciadv.abc4308

Article  PubMed  PubMed Central  Google Scholar 

Berti A, Bortolotti R, Dipasquale M et al (2021) Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer. Crit Rev Oncol/Hematol 162:103351. https://doi.org/10.1016/j.critrevonc.2021.103351

Article  PubMed  Google Scholar 

Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus Docetaxel in Advanced non-squamous non-small cell Lung Cancer. N Engl J Med 373:1627–1639. https://doi.org/10.1056/NEJMoa1507643

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bratman SV, Yang SYC, Iafolla MAJ et al (2020) Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer 1:873–881. https://doi.org/10.1038/s43018-020-0096-5

Article  CAS  PubMed  Google Scholar 

Cabel L, Riva F, Servois V et al (2017) Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study. Ann Oncol 28:1996–2001. https://doi.org/10.1093/annonc/mdx212

Article  CAS  PubMed  Google Scholar 

Cabel L, Proudhon C, Romano E et al (2018) Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. Nat Rev Clin Oncol 15:639–650. https://doi.org/10.1038/s41571-018-0074-3

Article  CAS  PubMed  Google Scholar 

Carbone DP, Reck M, Paz-Ares L et al (2017) First-line nivolumab in stage IV or recurrent non-small-cell Lung Cancer. N Engl J Med 376:2415–2426. https://doi.org/10.1056/NEJMoa1613493

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chaffer CL, Weinberg RA (2011) A perspective on Cancer Cell Metastasis. Science 331:1559–1564. https://doi.org/10.1126/science.1203543

Article  CAS  PubMed  Google Scholar 

Chaudhuri AA, Chabon JJ, Lovejoy AF et al (2017) Early detection of molecular residual disease in localized Lung Cancer by circulating Tumor DNA profiling. Cancer Discov 7:1394–1403. https://doi.org/10.1158/2159-8290.CD-17-0716

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chiou VL, Burotto M (2015) Pseudoprogression and Immune-related response in So-lid tumors. J Clin Oncol 33:3541–3543. https://doi.org/10.1200/JCO.2015.61.6870

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cristiano S, Leal A, Phallen J et al (2019) Genome-wide cell-free DNA fragmentation in patients with cancer. Nature 570:385–389. https://doi.org/10.1038/s41586-019-1272-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Castro G, Rizvi NA, Schmid P et al (2023) NEPTUNE: phase 3 study of First-Line Durvalumab Plus Tremelimumab in patients with metastatic NSCLC. J Thorac Oncol 18:106–119. https://doi.org/10.1016/j.jtho.2022.09.223

Article  CAS  PubMed  Google Scholar 

Diehl F, Schmidt K, Choti MA et al (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14:985–990. https://doi.org/10.1038/nm.1789

Article  CAS  PubMed  Google Scholar 

Dong ZY, Zhong WZ, Zhang XC et al (2017) Potential predictive value of TP53 and KRAS Mutation Status for response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res 23:3012–3024. https://doi.org/10.1158/1078-0432.CCR-16-2554

Article  CAS  PubMed  Google Scholar 

Duffy MJ, Crown J (2019) Biomarkers for Predicting Response to Immunotherapy with Immune checkpoint inhibitors in Cancer patients. Clin Chem 65:1228–1238. https://doi.org/10.1373/clinchem.2019.303644

Article  CAS  PubMed  Google Scholar 

Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME et al (2018) Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. Lancet Respiratory Med 6:771–781. https://doi.org/10.1016/S2213-2600(18)30284-4

Article  CAS  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026

Article  CAS  PubMed  Google Scholar 

Felip E, Altorki N, Zhou C et al (2021) Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 398:1344–1357. https://doi.org/10.1016/S0140-6736(21)02098-5

Article  CAS  PubMed  Google Scholar 

Ferrara R, Caramella C, Besse B, Champiat S (2019) Pseudoprogression in non–small cell Lung Cancer upon Immunotherapy: few drops in the Ocean? J Thorac Oncol 14:328–331. https://doi.org/10.1016/j.jtho.2018.12.011

Article  PubMed  Google Scholar 

Frelaut M, Du Rusquec P, De Moura A et al (2020) Pseudoprogression and Hyperprogression as New forms of response to Immunotherapy. BioDrugs 34:463–476. https://doi.org/10.1007/s40259-020-00425-y

Article  PubMed  Google Scholar 

Fricke J, Mambetsariev I, Pharaon R et al (2020) Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11. Med (Baltim) 99:e22323.